<DOC>
	<DOCNO>NCT00403442</DOCNO>
	<brief_summary>The purpose study explore combination PDT verteporfin reduce standard fluence rate , conjunction bevacizumab , treatment subfoveal CNV subtypes high percentage subretinal hemorrhage ( hemorrhage &gt; 50 % total lesion area ) . To assess safety bevacizumab combination verteporfin PDT ( reduce fluence : 300 mW/cm2 ) compare bevacizumab combination verteporfin PDT ( standard fluence : 600 mW/cm2 ) patient whose neovascular CNV lesion contain &gt; 50 % blood .</brief_summary>
	<brief_title>Bevacizumab Combination With Verteporfin Reduced Standard Fluence Treatment Hemorrhaged Lesions Neovascular AMD</brief_title>
	<detailed_description>This phase one study patient CNV lesion subtypes naïve previous treatment . Lesions must blood primary component ( i.e. , contain 50 % blood ) . Patients receive one two combination treatment : - Verteporfin PDT reduce fluence ( 300 mW/cm2 ) immediately follow bevacizumab ( 1.25 mg ) intravitreal injection - Verteporfin PDT standard fluence ( 600 mW/cm2 ) immediately follow bevacizumab ( 1.25 mg ) intravitreal injection A total 10 patient enrol , 5 per treatment arm .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>Patients men woman age 50 old . Patients diagnose subfoveal CNV due AMD lesion size ≤6 DA . Patients receive previous treatment subfoveal CNV , study eye . Patients visual acuity baseline 20/40 20/320 , evaluate ETDRS scale . Fluorescein Angiography show type subfoveal CNV baseline &gt; 50 % blood component total lesion area . Patients know hypersensitivity/allergy verteporfin , porfimer sodium , porphyrin , porphyria porphyrin sensitivity , hypersensitivity sunlight bright artificial light . Patients history glaucoma require treatment , currently antihypertensive treatment elevate intraocular pressure . Women childbearing potential must pregnant lactating , must negative pregnancy test screening must practice adequate method birth control . Patients treatment CNV study eye photodynamic therapy ( PDT ) , transpupillary thermotherapy ( TTT ) , local treatment ( e.g . submacular surgery , intravitreal triamcinolone , intraocular antiangiogenic agent ) . Previous laser photocoagulation therapy acceptable , provided subfoveal . Subject 's currently involve experimental procedure within last 12 week .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Macular Degeneration</keyword>
</DOC>